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Abstract
Background: Aspartyl (asparaginyl)-β-hydroxylase (AAH) hydroxylates Asp and Asn residues
within EGF-like domains of Notch and Jagged, which mediate cell motility and differentiation. This
study examines the expression, regulation and function of AAH, and its related transcripts,
Humbug and Junctin, which lack catalytic domains, using SH-Sy5y neuroblastoma cells.
Results: Real time quantitative RT-PCR demonstrated 8- or 9-fold higher levels of Humbug than
AAH and Junctin, and lower levels of all 3 transcripts in normal human brains compared with
neuroblastic tumor cells. AAH and Humbug expression were significantly increased in response to
insulin and IGF-I stimulation, and these effects were associated with increased directional motility.
However, over-expression of AAH and not Humbug significantly increased motility. Treatment
with chemical inhibitors of Akt, Erk MAPK, or cyclin-dependent kinase 5 (Cdk-5) significantly
reduced IGF-I stimulated AAH and Humbug expression and motility relative to vehicle-treated
control cells. In addition, significantly increased AAH and Humbug expression and directional
motility were observed in cells co-transfected with Cdk-5 plus its p35 or p25 regulatory partner.
Further studies demonstrated that activated Cdk-5 mediated its stimulatory effects on AAH
through Erk MAPK and PI3 kinase.
Conclusion: AAH and Humbug are over-expressed in SH-Sy5y neuroblastoma cells, and their
mRNAs are regulated by insulin/IGF-1 signaling through Erk MAPK, PI3 kinase-Akt, and Cdk-5,
which are known mediators of cell migration. Although AAH and Humbug share regulatory
signaling pathways, AAH and not Humbug mediates directional motility in SH-Sy5y neuroblastoma
cells.
Background
Aspartyl (Asparaginyl) β-Hydroxylase (AAH) is a Type 2
transmembrane protein that has a predicted molecular
mass of ~86 kD [1]. AAH is a member of the α-ketogluta-
rate-dependent dioxygenase family of molecules [2,3],
and catalyzes the hydroxylation of specific aspartyl and
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asparaginyl residues in EGF-like domains of certain pro-
teins [4,5]. The consensus sequence for AAH hydroxyla-
tion is present in Notch, Jagged, and extracellular matrix
molecules such as laminin and tenascin, which have dem-
onstrated roles in cell motility or adhesion [4,5]. The pro-
posed AAH hydroxylation reaction uses molecular oxygen
to form succinate, carbon dioxide, and 3-hydroxyaspartic
acid [6]. The catalytic domain resides within the carboxyl
terminus and corresponding ~52 kD cleavage product of
AAH [7].
The ~200 kB AAH gene encodes 3 proteins, AAH, Hum-
bug, and Junctin [5,8,9], which are generated by alterna-
tive splicing and exon sharing [5]. There are two AAH
mRNA transcripts that encode identical proteins, which
differ only in length of the 3'-untranslated region [1,5].
Humbug is derived from the first 13 exons of the AAH
gene, and lacks the C-terminal region that is responsible
for catalytic activity in AAH [4,5,9,10]. Junctin is the
smallest of the 4 transcripts, and contains Exons 1A, 2, 3,
4A, and 5A of the AAH gene [9]. Therefore, all 3 AAH-
related proteins share common N-terminal exons that
encode a trans-membrane domain in addition to a por-
tion of the cytoplasmic domain [4,9] but differ in the
length and function of the C-terminus.
AAH is abundantly expressed in a broad range of malig-
nant neoplasms and transformed cells lines, including
those of hepatic, biliary, breast, intestinal, pulmonary,
pancreatic, and neural origin, whereas most normal
mature tissues have relatively low levels of AAH [1,11-14].
However, placenta is a notable exception in that motile
and invasive trophoblasts express high levels of AAH
[1,15]. Initial studies established a convincing role for
AAH in malignancy by demonstrating transformation of
NIH3T3 cells that were stably transfected with the human
AAH cDNA, and partial reversal of the transformed phe-
notype in cells that were transfected with a dominant neg-
ative AAH mutant that lacked catalytic activity [11]. In situ
studies demonstrated that the highest levels of AAH
immunoreactivity were localized at the infiltrating mar-
gins of malignant neoplasms, rather than in their centers
[1,13,14]. The peripheral distribution of prominent AAH
immunoreactivity was not correlated with zonal differ-
ences in cell viability or proliferation [14], and corre-
spondingly, proliferation states that were un-related to
transformation, such as hepatocyte or bile duct regenera-
tion, and pre-malignant conditions such as primary scle-
rosing cholangitis, were found to have low (normal)
levels of AAH [11]. Therefore, enhanced AAH expression
is not correlated with cell proliferation per se. Instead, the
findings of increased AAH immunoreactivity along the
infiltrating margins of tumors and in metastatic foci
[1,13,14], together with the high levels of AAH in tro-
phoblastic cells, which are normally motile and invasive,
led us to hypothesize that AAH has a functional role in cell
motility [14,16].
Humbug is also abundantly expressed in malignant neo-
plasms of diverse histogeneses, including carcinomas of
hepatic, biliary, colonic, and pulmonary origin, as well as
various transformed cell lines [4,5,9,17]. Humbug can
bind calcium, and over-expression of Humbug results in
increased intracellular levels of calcium due to its release
from intracellular stores [9,10]. Thus far, Junctin expres-
sion has been characterized in skeletal and cardiac muscle
[5,9], but not in malignant neoplastic cells. Like Humbug,
Junctin has a role in regulating calcium release from the
sarcoplasmic reticulum [4,5,9,18,19]. In addition, Junctin
can physically associate with the ryanodine receptor com-
plex, and may have an important role in stabilizing the
complex [4,5,9,18,19]. Compared with AAH, less is
known about the possible function and expression of
Humbug and Junctin in relation to malignancy, tumor
progression, and motility.
In previous studies, a role for AAH in relation to motility
was demonstrated in part by the significantly reduced lev-
els of both AAH and directional motility observed in cells
that were transfected with antisense oligodeoxynucle-
otides that targeted the 5'end of AAH mRNA [14,16].
However, the molecular characterization of Humbug, its
structural relationship to AAH, high-level expression in
malignant neoplasms, and the realization that the anti-
sense oligodeoxynucleotides used in those experiments
would have also inhibited Humbug, prompted us to fur-
ther examine the expression and regulation of AAH, Hum-
bug, and Junctin, and determine if Humbug has a role in
cell motility. The strategy for examining the regulation
and function of AAH and related genes evolved from a
series of independent experiments demonstrating that: 1)
IGF-1 promotes migration of immature neuroblastic and
neuroblastoma cells [20-22]; 2) IGF-I can stimulate AAH
expression [17,23]; and 3) cyclin dependent kinase-5
(Cdk-5) is an important regulator of neuronal migration
in the developing central nervous system (CNS) [24-28].
The present work characterizes IGF-I regulation and
downstream signaling pathways through Erk MAPK, PI3
Kinase-Akt, and Cdk-5 that modulate AAH, Humbug, and
Junctin expression and directional motility in SH-Sy5y
human neuroblastoma cells.
Methods
Cell Culture
SH-Sy5y human neuroblastoma cells, and PNET1 and
PNET2 human CNS derived primitive neuroectodermal
tumor cells [29] were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 4 mM L-glutamine, 5 mM glucose, and
100  μM non-essential amino acids (Gibco-BRL, GrandBMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Island, NY). PNET1 cells are poorly differentiated and
exhibit rapid rates of proliferation, while PNET2 cells can
be differentiated and exhibit intact growth factor-medi-
ated signaling, similar to normal brain neurons [29]. To
examine growth factor modulation of AAH, Humbug, and
Junctin expression, sub-confluent cultures were serum
starved for 12 hours, then stimulated with IGF-1 (25 nM)
for up to 24 hours. Parallel cultures were stimulated with
insulin (50 nM) since insulin and IGF-1 share common
signaling mechanisms, or nerve growth factor (NGF; 2.5
ng/ml), which has distinct signaling mechanisms, but
promotes a range of neuronal functions including neurite
extension and motility [30,31]. To identify the signaling
pathways likely to mediate growth factor stimulated
effects on AAH, Humbug, and Junctin expression, the cells
were serum-starved over-night, then treated with a chem-
ical kinase inhibitor (Table 1), followed by IGF-1 stimula-
tion (serum-free medium) for 24 hours. The cells were
analyzed for AAH, Humbug, and Junctin mRNA expres-
sion as described below. Prior to conducting these experi-
ments, we demonstrated by in vitro kinase assay of SH-
Sy5y immunoprecipitates that, under the conditions
employed, the activity of each of the targeted kinases was
reduced by 80% or more relative to vehicle-treated control
cells (data not shown).
Human Brain Tissue Samples
Normal human frontal cortex tissue was obtained at post-
mortem examination from 6 adults and 2 infants (6 and
8 months old). In each case, the cause of death was under-
lying cardiac or pulmonary disease, and the post-mortem
intervals were less than 12 hours. The brain tissue samples
were originally collected and banked for use in research.
Adjacent blocks of fresh tissue were either fixed in neutral
buffered formalin or snap frozen in a dry ice-methanol
bath and stored at -80°C. Fixed tissue was embedded in
paraffin and histological sections stained with Luxol Fast
Blue-Hematoxylin and Eosin were used to confirm the
intactness of brain parenchyma. The fresh frozen tissue
was used to isolate RNA and measure gene expression by
real time quantitative RT-PCR. The use of human post-
mortem tissue in these studies was approved by the Rhode
Island Hospital-Lifespan Committee on the Protection of
Human Subjects Institutional Review Board.
Real Time Quantitative RT-PCR
Real time quantitative reverse transcriptase polymerase
chain reaction (RT-PCR) studies were used to measure rel-
ative mRNA abundance of AAH, Humbug, and Junctin.
Ribosomal (r) 18S levels measured in the same samples in
parallel reactions were used to calculate relative abun-
dance of each mRNA transcript [32]. Total RNA was iso-
lated from cells and brain tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufac-
turer's protocol. Samples containing 2 μg of RNA were
reverse transcribed using the AMV First Strand cDNA syn-
thesis kit (Roche Diagnostics Corporation, Indianapolis,
IN) and random oligodeoxynucleotide primers. PCR
amplifications were performed in 25 μl reactions contain-
ing reverse transcriptase products generated from 2.5 ng of
template, 300 nM each of gene specific forward and
reverse primer (Table 2), and 12.5 μl of 2× QuantiTect
SYBR Green PCR Mix (Qiagen Inc, Valencia, CA). The
amplified signals were detected continuously with the
BIO-RAD iCycler iQ Multi-Color Real time PCR Detection
System (Bio-Rad, Hercules, CA). The amplification proto-
col was as follows: initial 10-minute denaturation and
enzyme activation at 95°C, followed by 40 cycles of 95°C
× 15 sec, 55°–60°C × 30 sec, and 72°C × 30 sec. Anneal-
ing temperatures were optimized using the temperature
gradient program provided with the iCycler software.
AAH, Humbug, Junctin, and 18S RNA transcripts were
simultaneously evaluated in parallel reactions using aliq-
uots of the same cDNA templates [32]. Serial dilutions of
known quantities of recombinant plasmid DNA contain-
ing AAH, Humbug, Junctin, or 18S cDNA target sequences
were used as standards in the PCR reactions, and the
regression lines generated from the Ct values of the stand-
ards were used to calculate mRNA abundance. The results
were normalized to 18S because 18S rRNA is highly abun-
dant and essentially invariant, whereas housekeeping
gene expression frequently varies with growth factor stim-
ulation or treatment with kinase modulators. Inter-group
statistical comparisons were made using the calculated ng
ratios of AAH/18S, Humbug/18S, and Junctin/18S. In pre-
liminary studies, the SYBR Green-labeled PCR products
were evaluated by agarose gel electrophoresis, and the
authenticity of each amplicon was verified by nucleic acid
sequencing.
Western Blot Analysis
Cell homogenates were prepared in radio-immunoprecip-
itation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5, 1%
NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM
EDTA, 2 mM EGTA) containing protease (1 mM PMSF,
0.1 mM TPCK, 1 μg/ml aprotinin, 1 μg/ml pepstatin A, 0.5
Table 1: Kinase inhibitors
Inhibitor Target* Concentration (μM)
PD98059 Erk MAPK 20
SB202190 p38 MAPK 10
Akt inhibitor Akt 8
LiCl GSK-3β 20
Roscovitine Cdk-5 100
H-89 PKA 2
*Erk: extracellular signal-regulated kinase; MAPK: mitogen associated 
protein kinase; GSK: Glycogen Synthase Kinase; cdk: cyclin-dependent 
kinase; PKA: Protein Kinase ABMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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μg/ml leupeptin, 1 mM NaF, 1 mM Na4P2O7) and phos-
phatase (2 mM Na3VO4) inhibitors. Protein concentra-
tions were determined using the bicinchoninic acid (BCA)
assay (Pierce, Rockford, IL). Samples containing 60 μg of
protein were fractionated by sodium dodecyl sulfate,
polyacrylamide gel electrophoresis (SDS-PAGE) [33]. The
proteins were transferred to Immobilon-P (Millipore Cor-
poration, Bedford, MA) PVDF membranes and non-spe-
cific binding sites were adsorbed with SuperBlock-TBS
(Pierce, Rockford, IL). The membranes were then incu-
bated over night at 4°C with primary antibody (1 μg/ml)
diluted in Tris-buffered saline (TBS; 50 mM Tris, 150 mM
NaCl, pH 7.4) containing 1% bovine serum albumin and
0.05% Tween-20 (TBST-BSA). Immunoreactivity was
detected using horseradish peroxidase (HRP) conjugated
IgG (Pierce, Rockford, IL), Western Lightning chemilumi-
nescence reagents (Perkin Elmer Life Sciences Inc., Bos-
ton, MA), and digital imaging with the Kodak Digital
Science Imaging Station (NEN Life Sciences, Boston, MA).
Microtiter Immunocytochemical ELISA (MICE) assay
The MICE assay is a rapid and sensitive method of quan-
tifying immunoreactivity in 96-well micro-cultures [34].
The cells were fixed for 24 hours in Histochoice (Amresco,
Solon, Ohio), permeabilized with 0.05% saponin in Tris-
buffered saline (50 mM Tris, pH 7.5, 0.9% NaCl; TBS),
and blocked with SuperBlock-TBS (Pierce, Rockford, IL).
The cells were incubated overnight at 4°C with primary
antibody diluted in TBS containing 0.05% Tween-20 and
0.5% bovine serum albumin (TBST-BSA). Immunoreac-
tivity was detected with horseradish peroxidase conju-
gated secondary antibody (Pierce, Rockford, IL) and the
TMB soluble peroxidase substrate (Pierce, Rockford, IL).
Absorbances were measured at 450 nm using a Spectra-
count plate reader (Packard Instrument Co., Meriden,
CT).
To compare the levels of protein expression it was neces-
sary to correct for differences in cell density. After measur-
ing immunoreactivity, the plates were washed in TBS and
the cells were stained 0.1% Coomassie blue dye in 40%
methanol/10% acetic acid. After extensive washing in
water, the plates were dried and then the dye was eluted
from the adherent cells with PBS containing 1% SDS (200
μl/well). The absorbances (560 nm) were measured using
a Spectracount plate reader (Packard Instrument Com-
pany, Meriden, CT). The MICE index was calculated from
the ratio of the absorbances measured for immunoreactiv-
ity and cell density multiplied by 100. Coomassie blue
absorbance also increases linearly with cell density
between 1 × 104 and 5 × 105 cells per well. At least 8 inde-
pendent replicate cultures were analyzed in each experi-
ment, and all experiments were repeated 3 times.
Transfection of SH-Sy5y Cells
The full-length human AAH cDNA was ligated into the
pcDNA5/FRT/TO vector (Invitrogen Corporation,
Carlsbad, CA), in which gene expression was regulated by
a CMV promoter (pAAH). Humbug was sub-cloned from
the AAH cDNA by PCR amplification using the following
primer pairs: Forward: 5'-CGG GAT CCA TGG CCC AGC
GTA-3', Reverse: 5'-GCC TCG AGC CCC TTT TAC GGA G-
3'. The Humbug PCR product was gel purified and ligated
into the pCR3.1 mammalian expression vector (pHMBG;
Invitrogen Corporation, Carlsbad, CA) in which gene
expression is under the control of a CMV promoter. Ori-
entation and authenticity of the cloned PCR product were
verified by sequencing and transient transfection studies.
As control, cells were transfected with recombinant plas-
mid expressing the luciferase gene (pLuc) that was ligated
into the pcDNA3.1 vector (Invitrogen Corporation,
Carlsbad, CA) in which gene expression was regulated by
a CMV promoter.
Table 2: Real time PCR primer pairs
Primer* Sequence (5'→3') Amplicon Size (bp)
18 S For GGACCAGAGCGAAAGCATTTGCC
18 S Rev TCAATCTCGGGTGGCTGAACGC 50
AAH For GGGAGATTTTATTTCCACCTGGG
AAH Rev CCTTTGGCTTTATCCATCACTGC 256
Humbug For GCTGGGTTGATTGAGGATGTGTG
Humbug Rev GCAGGGGGAAAAAGTCACCTTATC 301
Junctin For CCTGAGTCAAGGAAGGAAAGTAAG
Junctin Rev GCCGTTTCTTTTCTGGGTATTTCC 308
IRS-1 For TGCTGGGGGTTTGGAGAATG
IRS-1 Rev GGCACTGTTTGAAGTCCTTGACC 68
IRS-2 For AAAATTGGCGGAGCAAGGC
IRS-2 Rev ATGTTCAGGCAGCAGTCGAGAG 64
IRS-4 For CCGACACCTCATTGCTCTTTTC
IRS-4 Rev TTTCCTGCTCCGACTCGTTCTC 74
*For-forward; Rev-reverse; AAH = aspartyl (asparaginyl)-β-hydroxylase; IRS = insulin receptor substrateBMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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To examine the effects of AAH or Humbug over-expres-
sion on directional motility, parallel cultures seeded into
35 mm2 wells with 105 cells/well were transiently trans-
fected with 4 μg plasmid DNA expressing AAH (pAAH),
Humbug (pHMBG), or luciferase (pLuc; negative con-
trol), using Lipofectamine 2000 (Invitrogen Corporation,
Carlsbad, CA) according to the manufacturer's protocol.
To evaluate the role of Cdk-5 in relation to AAH, Hum-
bug, and Junctin expression and motility, SH-Sy5y cells
were transiently transfected with recombinant plasmids
expressing Cdk-5, its regulatory partners, p25 or p35, Cdk-
5+p25, or Cdk-5+p35, each of which was under the con-
trol of a CMV promoter. Cells were transfected with 2 μg
of each recombinant plasmid. However, to over-express a
single gene, cells were co-transfected with 2 μg recom-
binant plasmid + 2 μg empty vector. The use of Lipo-
fectamine 2000 resulted in transfection efficiencies of
50%-60% in SH-Sy5y cultures, as demonstrated by co-
transfection with a green fluorescent protein (GFP)
reporter construct and fluorescence microscopy. In addi-
tion, transfection efficiency, time course, and peak period
of gene expression were determined by luciferase assay
(Promega, Madison, WI) of cells co-transfected with
equivalent amounts of pLuc (0.5 μg). Finally, studies were
performed to demonstrate that trypsinization and re-seed-
ing of transiently transfected cells into fresh chambers did
not significantly alter the course of transgene expression
(luciferase activity) (data not shown), indicating that tran-
siently transfected cells could be used in directional motil-
ity assays.
Motility Assay
Directional motility was measured using the ATP Lumi-
nescence-Based Motility/Invasion (ALMI) assay [35].
Briefly, 200 μl of medium containing 25 nM IGF-1 was
placed in the bottom of each blind well chamber (Neuro
Probe, Gaithersburg, MD). An 8 μM pore diameter poly-
carbonate membrane was seated just above the trophic
factor-containing medium and tightly fixed in place with
the screw cap that formed the upper chamber. 100,000
viable cells (demonstrated by Trypan Blue exclusion) were
seeded into the upper chamber in serum-free medium.
Migration was allowed to proceed for 30 minutes at 37°C
in a conventional CO2  incubator. The ATPLite assay
(Packard Instrument Company, Meriden, CT) was used to
quantify the number of cells remaining on upper surface
of the membrane (non-migrated), located on the under-
surface of the membrane (migrated, adherent), or distrib-
uted in the lower chamber (migrated, non-adherent) since
the ATP levels are linearly correlated with cell number
between 103 and 5 × 105 cells [35].
To measure ATP luminescence, non-motile cells were
removed from the upper surface of the membrane using a
cotton swab. The cells were lysed by immediately sub-
merging the swabs in 200 μl of diluted ATP lysis solution
in a well of a black 96-well microplate. Completeness of
cell harvesting was monitored microscopically. Cells
adherent to the undersurface of the membrane were har-
vested and lysed by submerging the wiped membrane in
200 μl of diluted ATP lysis solution in a second well of a
black microplate. Cells in the lower chamber were resus-
pended and added directly to 25 μl of undiluted ATP lysis
solution in a third well of a black microplate. After 5-min-
utes incubation with agitation to ensure complete cell
lysis, ATPLite substrate (25 μl) was added to each well.
The reactions were mixed for 2 minutes by gentle platform
agitation. Subsequently, the plates were dark adapted for
5 minutes and then luminescence was measured in a Top-
Count Microplate reader (Packard Instrument Company,
Meriden, CT). The percentages of non-motile, motile
adherent, motile non-adherent cells were calculated for
each assay. Experiments were performed in replicates of 6
or 8 per variable using independent cultures.
Source of Reagents
Mouse monoclonal antibodies to AAH were generated
against recombinant protein [1]. All kinase inhibitors
were purchased from CalBiochem (Carlsbad, CA). The
recombinant plasmids encoding Cdk-5, p35, and p25
were generously provided by Dr. Li-Hue Tsai at Harvard
Medical School, Boston, MA.
Statistical Analysis
Data depicted in the graphs represent the means ± S.D.'s
of results obtained from 3 to 8 independent replicate
assays. Inter-group statistical comparisons were made
using Analysis of Variance (ANOVA) and the Fisher Least
Significant Difference (LSD) post-hoc test with the
Number Cruncher Statistical Systems, Version 2004 (Dr.
Jerry L. Hintze, Kaysville, UT).
Results
Profiles of AAH, Humbug, and Junctin Expression in SH-
Sy5y Neuroblastoma Cells
Real time quantitative RT-PCR studies were used to exam-
ine the expression profiles and levels of AAH, Humbug,
and Junctin mRNA in SH-Sy5y cells. In addition, human
CNS-derived primitive neuroectodermal tumor cells
(PNET1 and PNET2) and normal infant (N = 2) and adult
(N = 6) human postmortem brain tissue (frontal cortex)
were studied. Humbug was expressed at significantly (8 or
9 fold) higher levels than AAH or Junctin in SH-Sy5y cells
(P < 0.001). In addition, the levels of AAH and Humbug
mRNA were significantly higher in SH-Sy5y cells com-
pared with PNET cells and normal human brain tissue
(Figures 1A and 1B). In PNET1 cells, Humbug and Junctin
mRNA transcripts were similarly abundant and both were
more highly expressed than AAH (P < 0.001) (Figure 1).
PNET1 cells are poorly differentiated and proliferate moreBMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Comparison of AAH (A), Humbug (B), and Junctin (C) mRNA levels in SH-Sy5y, CNS-derived PNET1 and PNET2 primitive  neuroblastic cells, normal human infant frontal cortex, and normal human adult frontal cortex Figure 1
Comparison of AAH (A), Humbug (B), and Junctin (C) mRNA levels in SH-Sy5y, CNS-derived PNET1 and PNET2 primitive 
neuroblastic cells, normal human infant frontal cortex, and normal human adult frontal cortex. RNA was reverse transcribed 
with random oligodeoxynucleotide primers, and the cDNA templates were used to measure gene expression by real time 
quantitative PCR. The results were normalized to 18S measured in the same samples. The graphs depict the mean ± S.D. of 
results obtained from 6 replicate independent cultures, 2 infant brains, and 6 adult brains. Inter-group comparisons were made 
using ANOVA with post-hoc Fisher Least Significant Difference (LSD) tests (+ P < 0.05; * P < 0.001 relative to Sh-Sy5y cells in 
A and B, and relative to PNET1 cells in C).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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rapidly compared with PNET2 cells [29]. PNET1 and
PNET2 cells are less differentiated than normal infant
brains, and infant brains are less differentiated than adult
brains. Correspondingly, the highest levels of AAH, Hum-
bug, and Junctin were measured in PNET1 followed by
PNET2 cells, infant brain, and then adult brain (Figures
1A–1C). Moreover, in 4 of the 6 adult brain samples, AAH
mRNA transcripts were not detected. It is noteworthy that
the mean levels of 18S rRNA were similar in all groups
(data not shown).
Insulin/IGF-1 stimulation of AAH expression and motility
Sub-confluent cultures of SH-Sy5y cells were serum-
starved over night, then stimulated with insulin, IGF-1,
NGF, or vehicle in serum-free medium for 24 hours. NGF
was used as a control because it utilizes signaling mecha-
nisms distinct from those of insulin and IGF-1, and pro-
motes neuronal differentiation [31,36]. AAH protein
expression was examined by Western blot analysis and the
microtiter immunocytochemical ELISA (MICE) assay,
directional motility was measured using the ATP Lumi-
nescence-based Motility/Invasion (ALMI) assay, and
AAH, Humbug, and Junctin mRNA levels were measured
by real time quantitative RT-PCR. Western blot analysis
using the HBOH monoclonal antibody, which binds to a
carboxyl terminal epitope present in AAH and not Hum-
bug, demonstrated higher levels of AAH (~86 kD) in insu-
lin and IGF-1-stimulated relative to NGF-stimulated and
vehicle-treated control cultures (Figure 2A, upper panel).
Equal loading of protein was demonstrated by probing
the blots with antibodies to β-actin (Figure 2A, lower
panel). Using the MICE assay which measures immunore-
activity directly in cultured cells with results normalized
to culture cell density, we demonstrated significantly
higher mean levels of AAH protein in insulin- and IGF-I-
stimulated relative to un-stimulated cells (Figure 2B).
Directional motility was measured using the ALMI assay
in which SH-Sy5y cells stimulated with vehicle, insulin, or
IGF-I for 30 minutes and the mean total percentages of
motile (motile-adherent + motile-non-adherent) cells
were determined. The results demonstrated significantly
higher mean directional motility indices in insulin- (P <
0.001) and IGF-1-stimulated (P < 0.001) relative to un-
stimulated control cells (Figure 2C). In addition, IGF-I
stimulated cells had a higher mean motility index than
insulin-stimulated cells (P < 0.05) due to a further
increase in the percentage of motile-adherent cells
(migrated through the pores but remaining adherent to
the membrane) within the population (data not shown).
We next compared the effects of insulin and IGF-I stimu-
lation on AAH, Humbug and Junctin mRNA expression in
SH-Sy5y cells by real time quantitative RT-PCR. As con-
trols, parallel cultures were either treated with vehicle or
NGF. Corresponding with results obtained by Western
blot analysis or the MICE assay, the mean levels of AAH
mRNA were significantly higher in the insulin- and IGF-1-
stimulated relative to vehicle treated and NGF-stimulated
cells (P < 0.001; Figure 2D). Humbug mRNA levels were
significantly increased in response to IGF-1, insulin, and
NGF relative to no growth factor treatment (P < 0.001; Fig-
ure 2E). In contrast, Junctin mRNA levels were not stimu-
lated and instead were relatively suppressed with growth
factor stimulation (Figure 2F).
Potential Roles of AAH and Humbug in Relation to SH-
Sy5y Cell Motility
In previous studies, transfection with antisense oligodeox-
ynucleotides that targeted the 5' region of AAH mRNA sig-
nificantly inhibited both AAH expression and motility
[14,16]. However, with the additional data generated
regarding the expression profiles of AAH and Humbug, it
was important to determine if AAH, Humbug, or both
have critical roles in regulating motility in SH-Sy5y cells.
To conduct these experiments, SH-Sy5y cells were tran-
siently transfected with cDNAs encoding AAH (pAAH),
humbug (pHMBG), or luciferase (pLuc) in which gene
expression was under the control of a CMV promoter. Co-
transfection of pAAH and pHMBG with pLuc demon-
strated equal transfection efficiencies among the groups
(data not shown). Selectively increased transgene expres-
sion was verified by real time RT-PCR (Figures 3A–3B).
Directional motility measured 48 hours after transfection
using the ALMI assay demonstrated significantly higher
mean motility indices in cells transfected with pAAH rela-
tive to those transfected with pHMBG or pLuc (P < 0.005),
and similar mean motility indices in cells transfected with
pHMBG or pLuc (Figure 3C).
Pathways Mediating Insulin/IGF-1 Stimulated AAH and 
Humbug Expression
Results shown in Figure 2 demonstrate that AAH and
Humbug expression are modulated by insulin and IGF-1
stimulation. Insulin and IGF-1 mediate their effects by
activating complex intracellular signaling pathways that
are initiated by ligand binding to cell surface receptors
and attendant activation of intrinsic receptor tyrosine
kinases [37]. Insulin/IGF-1 receptor tyrosine kinases
phosphorylate insulin receptor substrates (IRS) molecules
[38], which transmit signals downstream through Erk
MAPK and PI3 kinase/Akt and inhibiting glycogen syn-
thase kinase-3β (GSK-3β) to promote growth, survival,
and motility [39-46].
Initial studies characterized the signaling pathways that
are likely to mediate insulin and IGF-1 signaling in SH-
Sy5y neuroblastoma cells. Real time quantitative RT-PCR
was used to determine which IRS proteins are most abun-
dantly expressed and how their expression levels are mod-BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Modulation of AAH, Humbug, and Junctin expression by growth factor stimulation Figure 2
Modulation of AAH, Humbug, and Junctin expression by growth factor stimulation. Subconfluent SH-Sy5y cell cultures were 
serum starved over night then stimulated with vehicle (CON), insulin (50 nM), IGF-1 (25 nM), or NGF (2.5 ng/ml) for 24 hours. 
(A) Upper panel: Representative Western blot demonstrating AAH protein expression (~86 kD) using the HBOH monoclonal 
antibody. Immunoreactivity was detected with horseradish peroxidase conjugated secondary antibody, ECL reagents, and dig-
ital imaging. Lower panel-blots were stripped and re-probed to detect β-actin as a loading control. The positions of molecular 
weight standards included in the analysis are indicated at the left. (B) AAH immunoreactivity was measured directly in 96-well 
micro-cultures using the microtiter immunocytochemical ELISA (MICE) assay. The MICE index corresponds to immunoreactiv-
ity corrected for cell density. (C) Directional motility was measured in response to insulin or IGF-I stimulation using the ATP 
Luminescence-Based Motility/Invasion (ALMI) assay. The total percentages of motile cells (motility index), both adherent and 
non-adherent, were calculated (see Methods). (D-F) AAH, Humbug, and Junctin mRNA levels were measured by real time 
quantitative RT-PCR with results normalized to 18S. See Methods section for detailed protocols. Graphs depict mean ± S.D. of 
results obtained from 6 or 8 replicate independent cultures. Data were analyzed using ANOVA with the Fisher Least Significant 
Difference post-hoc test (+P < 0.05; *P < 0.001 relative to control).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Over-expression of AAH and not Humbug increases motility in SH-Sy5y cells Figure 3
Over-expression of AAH and not Humbug increases motility in SH-Sy5y cells. SH-Sy5y cells were transfected with recom-
binant plasmid DNA to express luciferase (pLuc), AAH (pAAH), or Humbug (pHMBG). 48 hours after transfection during the 
peak period of gene expression, the cells were harvested to measure (A) AAH and (B) Humbug expression by real time quan-
titative RT-PCR with levels were normalized to 18S, and (C) directional motility using the ATPLite luminescence-based motil-
ity/invasion (ALMI) assay (see Methods). For the ALMI assays, percent motile refers to the combined mean percentage of 
motile adherent+motile non-adherent populations. The graphs depict the mean ± S.D. of results obtained from 6 or 8 replicate 
independent cultures. Within group comparisons were made using ANOVA with post-hoc Fisher Least Significant Difference 
(LSD) tests (* P < 0.001 relative to the other groups studied).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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ulated with growth factor stimulation, and Western blot-
immunoprecipitation studies were used to examine insu-
lin/IGF-1 stimulated IRS-associated PI3 kinase activity.
The real time quantitative RT-PCR studies using cells
maintained in medium containing 5% FCS demonstrated
that IRS-1 was the most abundantly expressed, followed
by IRS-4, while IRS-2 was the least abundant of the IRS
molecules expressed in SH-Sy5y cells (Table 3). IRS-3 was
not studied because expression of this mRNA species is
restricted to rodent adipose tissue [47]. In cultures that
were stimulated with insulin or IGF-1 for 24 hours, IRS-1
mRNA levels were still highest followed by IRS-4, but IRS-
1 was more abundantly expressed with IGF-1 stimulation,
whereas IRS-2 and IRS-4 were more abundant in the insu-
lin stimulated cells (Table 3). Corresponding with the real
time RT-PCR results, IRS-1, tyrosyl-phosphorylated IRS-1,
and p85-associated IRS-1 immunoreactivity were detected
by immunoprecipitation and Western blot analysis in
both insulin and IGF-1 stimulated cells, whereas IRS-2
and IRS-4 were difficult to detect (data not shown). These
findings suggest that insulin and IGF-1 signaling are
mainly transmitted through IRS-1 as opposed to IRS-2 or
IRS-4 in SH-Sy5y cells.
To characterize the downstream signaling pathways that
modulate AAH and Humbug expression, real time quan-
titative RT-PCR was used to measure AAH, Humbug, and
Junctin mRNA levels in cells that were stimulated with
insulin or IGF-1 and pre-treated with a chemical inhibitor
of Erk MAPK (PD98059), p38 MAPK (SB202190), Akt
(Akt inhibitor), GSK-3β (LiCl), cyclin dependent kinase 5
(Cdk-5; Roscovitine), or protein kinase A (H-89) (Table
1). The control cells were treated with vehicle. Studies of
Cdk-5 were included because Cdk-5 is abundantly
expressed in neurons and has a probable role in neuronal
migration during development [26-28,48]. Since the
results for insulin and IGF-1 with respect to AAH expres-
sion were similar, only data generated with IGF-1 stimu-
lated cells are illustrated (Figure 4). The studies
demonstrated significantly reduced levels of both AAH
and Humbug mRNA in cells that were treated with
PD98059, Akt inhibitor, or Roscovitine (P < 0.001),
which inhibit Erk MAPK, Akt, and Cdk-5, respectively
(Figures 4A and 4B). In addition, Humbug, but not AAH
mRNA expression, was significantly reduced by treatment
with SB202190, which inhibits p38 MAPK. Neither AAH
nor Humbug mRNA levels were significantly modulated
by treatment with H-89 (PKA inhibitor) or LiCl (GSK-3β
inhibitor). Junctin mRNA transcripts were not signifi-
cantly modulated by any of the kinase inhibitors, with the
exception of H-89, which reduced the mean mRNA level
by 40% relative to vehicle treated control cells (P < 0.05;
Figure 4C).
Effects of Erk MAPK, Akt, PI3 Kinase, or Cdk-5 Inhibition 
on AAH Protein Expression and Directional Motility in SH-
Sy5y Cells
SH-Sy5y cells that were stimulated with IGF-1 for 24
hours in the presence or absence of kinase inhibitor were
used to measure AAH protein by Western blot analysis
(Figures 5A and 5B) and the MICE assay (Figure 5C). In
addition, directional motility was measured using the
ALMI assay (Figure 5D). Western blot analysis with the
HB-OH monoclonal antibody detected the expected ~86
kD AAH protein in all samples. AAH protein levels were
similarly abundant in cells treated with vehicle,
SB202190, or H89 (Figures 5A–5B). In contrast, cells
treated with Roscovitine, PD98059, Akt inhibitor, or
LY294002 had significantly lower levels of AAH protein,
and cells treated with LiCl had significantly higher levels
of AAH protein relative to control (Figures 5A–5B). Equal
loading of protein samples was demonstrated by probing
the blots with antibodies to β-actin (Figure 5A). The MICE
assay results also demonstrated significantly reduced AAH
immunoreactivity in cells treated with the Akt inhibitor,
Roscovitine, or PD98059, and increased AAH protein in
cells treated with LiCl, which inhibits GSK-3β (Figure 5C).
Correspondingly, cells pre-treated with inhibitors of Akt,
Erk MAPK, or Cdk-5 had significantly reduced mean total
motility indices, while cells pre-treated with LiCl had sig-
nificantly increased motility (Figure 5D). Pre-treatment
with SB202190 had no significant effect on mean total
motility relative to control. In essence, the effects of chem-
ical kinase inhibitor treatment on AAH protein levels cor-
related with their effects on directional motility.
Table 3: Levels of Insulin Receptor Substrate Expression in SH-Sy5y Cells
Growth Factor IRS-1/18S × 10-6 IRS-2/18S × 10-6 IRS-4/18S × 10-6
Control 7.18 ± 0.88*, + 1.19 ± 0.21 1.37 ± 0.27
Insulin 18.66 ± 2.21*, ++ 2.18 ± 0.44 + 3.96 ± 0.61 +
IGF-1 32.61 ± 2.55*, ++ 1.37 ± 0.24 2.01 ± 0.21 +
SH-Sy5y cells were stimulated with vehicle (Control), 50 nM insulin, or 25 nM IGF-1 for 24 hours, then analyzed by real time quantitative RT-PCR 
to measure mRNA levels of insulin receptor substrate (IRS) subtypes 1, 2, and 4 using the primer pairs listed in Table 2. The results were 
normalized to 18S ribosomal RNA measured in the same samples. The values listed represent mean ± S.D. of results obtained from 6 replicate 
cultures. *P < 0.001 relative to IRS-2 and IRS-4 measured in the same cultures. ++ P < 0.001; + P < 0.05 relative to control.BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Effects of chemical kinase inhibitors on (A) AAH, (B) Humbug, and (C) Junctin mRNA levels in IGF-I stimulated SH-Sy5y cells Figure 4
Effects of chemical kinase inhibitors on (A) AAH, (B) Humbug, and (C) Junctin mRNA levels in IGF-I stimulated SH-Sy5y cells. 
Subconfluent cultures were serum starved over night, then stimulated with IGF-1 and treated with vehicle (Con), or a chemical 
inhibitor of Akt, PKA (H-89), GSK-3β (LiCl), Erk MAPK (PD98059-PD9), Cdk-5 (Roscovitine-Rosc), or p38 MAPK (SB202190-
SB2). Inhibitor concentrations are listed in Table 1. After 24 hours of growth factor stimulation, cells were harvested to meas-
ure (A) AAH, (B) Humbug, and (C) Junctin expression by real time quantitative RT-PCR as described in the legend for Figure 1. 
The mRNA levels were normalized to 18S rRNA levels measured in the same samples, and the graphs depict the mean ± S.D. 
of results. Statistical comparisons were made using ANOVA and post hoc Fisher LSD tests (**P < 0.001; *P < 0.01 relative to 
control).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Cdk-5 Modulation of AAH Expression and Motility
Since the effects of PI3 Kinase/Akt and Erk MAPK have
been well documented in relation to growth and motility
in various cell types [49-52], we focused further studies to
characterize Cdk-5 modulation of AAH, Humbug and
Junctin expression as well as directional motility. Cdk-5
activity is increased by the interaction of Cdk-5 protein
with one of its regulatory partners, p35 or p25 [26-28].
p35 has a relatively short half-life which may be impor-
tant for the on-off regulation of Cdk-5 kinase activity,
whereas p25, the truncated, C-terminal fragment of p35
[26-28,53-56], has a prolonged half-life and leads to con-
stitutive activation of Cdk-5 kinase [53,55-58]. To exam-
ine the effects of Cdk-5 on AAH expression and motility,
SH-Sy5y cells were transfected with recombinant plasmid
expressing Cdk-5, the p25 or p35 regulatory partner of
Cdk-5, Cdk-5+p25, or Cdk-5+p35. Cells transfected with
pLuc or empty vector (pcDNA3.1) served as negative con-
trols. In all cases, gene expression was under the control of
a CMV promoter. The analyses were performed 48 hours
after transfection, corresponding with the peak period of
gene expression. For each experiment, the amount of
Effects of chemical kinase inhibitors on AAH protein expression and directional motility in IGF-I stimulated SH-Sy5y cells Figure 5
Effects of chemical kinase inhibitors on AAH protein expression and directional motility in IGF-I stimulated SH-Sy5y cells. Sub-
confluent cultures were serum starved over night, then stimulated with IGF-1 and treated with vehicle (Con), or a chemical 
inhibitor of Akt, PKA (H-89), GSK-3β (LiCl), Erk MAPK (PD98059-PD9), Cdk-5 (Roscovitine-Rosc), or p38 MAPK (SB202190-
SB2). Inhibitor concentrations are listed in Table 1. After 24 hours of growth factor stimulation, cells were harvested to meas-
ure AAH protein by (A) Western blot analysis with (B) digital imaging, or (C) they were analyzed directly in 96-well micro-cul-
tures using the MICE assay. (D) Directional motility was measured using the ALMI assay (see Methods). (A-lower panel) For 
Western blot controls, the blots were stripped and re-probed with monoclonal antibodies to β-actin. The graphs depict the 
mean ± S.D. of results. Statistical comparisons were made using ANOVA and post hoc Fisher LSD tests (*P < 0.001 relative to 
control).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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recombinant plasmid and the total quantity of DNA
transfected were held constant. To achieve this, empty vec-
tor (pcDNA3.1) was used to equalize DNA loading. Cdk-
5 activity was measured with in vitro kinase assays using
immunoprecipitates and H1 histone as substrate as previ-
ously described [58].
Although cells transfected with Cdk-5, p25, p35, Cdk-
5+p25, or Cdk-5+p35 all had significantly increased levels
of Cdk-5 activity relative to pLuc-transfected cells, the
highest levels of Cdk-5 activity were achieved by transfect-
ing cells with Cdk-5+p25 (Figure 6A). In contrast, cells
transfected with pAAH had low levels of Cdk-5 activity,
similar to the pLuc-transfected control cells. The transfec-
tion efficiencies were similar as demonstrated with a Luci-
ferase reporter assay (Figure 6B). To determine the effects
of increased Cdk-5 activity on AAH expression and motil-
ity, AAH protein and mRNA levels were measured by
Western blot analysis (Figure 6C) with digital image
quantification (Figure 6D), and real time quantitative RT-
PCR (Figure 6E). Directional motility was measured using
the ALMI assay (Figure 6F). Cells transfected with p35,
p25, Cdk-5+p35, or Cdk-5+p25 had significantly higher
levels of AAH protein expression (Figures 6C and 6D) rel-
ative to control cells. In contrast, β-actin expression was
similar among the groups (Figure 6C). Cells transfected
with p25, Cdk-5+p35, or Cdk-5+p25 also had signifi-
cantly increased levels of AAH mRNA as demonstrated by
real time quantitative RT-PCR (Figure 6E). The directional
motility assay results, for the most part, paralleled Cdk-5
activation and AAH expression in that the highest mean
directional motility indices were observed in cells trans-
fected with p25, Cdk-5+p35 or Cdk-5+p25 (Figure 6F). In
contrast, directional motility was not significantly
increased in cells transfected with Cdk-5 or p35 relative to
control.
For comparison, we also examined the effects of Cdk-5
activation on Humbug and Junctin expression. Real time
quantitative RT-PCR studies demonstrated significantly
higher levels of Humbug expression in cells transfected
with Cdk-5+p25 or Cdk-5+p35 relative to cells transfected
with pLuc, Cdk-5, p25, or p35 (P < 0.001), whereas the
cells transfected with Cdk-5+p25 or Cdk-5+p35 had simi-
larly high levels of Humbug (Figure 7A). In contrast, Junc-
tin mRNA levels were not significantly increased in cells
transfected with any of the cDNA constructs used, and
instead, Junctin mRNA expression was significantly
decreased in cells that were transfected with p35 or Cdk-
5+p35 (Figure 7B).
Cdk-5 Mediates Its Effects on AAH and Humbug 
Expression Through Erk MAPK and PI3-Kinase
To determine if the effects of Cdk-5 on AAH and Humbug
expression were mediated downstream through Erk or PI3
kinase, AAH, Humbug, and Junctin mRNA levels were
measured in cells transfected with pLuc or Cdk-5+p25. 24
hours prior to harvesting the cells, parallel cultures were
treated with PD98059 or LY294002 to inhibit Erk MAPK
or PI3 kinase, respectively. Cells transfected with the Cdk-
5+p25 had increased AAH and Humbug, but not Junctin
mRNA levels by real time quantitative RT-PCR, as
described above. However, pre-treatment with PD98059
or LY294002 significantly inhibited AAH, Humbug, and
Junctin expression, and with regard to Humbug and Junc-
tin, the inhibition of gene expression occurred independ-
ent of Cdk-5+p25 over-expression (Figures 8A–8C).
Discussion
Profiles of AAH, Humbug, and Junctin Expression in SH-
Sy5y Neuroblastoma Cells and Normal Human Brain
The studies demonstrated expression of all 3 AAH-related
mRNA transcripts in SH-Sy5y neuroblastoma cells and
CNS-derived PNET cells, with Humbug being the most
abundant. PNET2 cells, which are of CNS origin, had sim-
ilar profiles of AAH, Humbug, and Junctin mRNA tran-
scripts compared with normal infant brains. The
significantly higher levels of AAH and Humbug in SH-
Sy5y and PNET cells compared with normal brain are con-
sistent with previous reports demonstrating considerably
higher levels of AAH and Humbug in transformed com-
pared with non-transformed cells [1,10,12-14,17]. In
addition, the higher levels of AAH, Humbug, and Junctin
in infant compared with adult human brains suggest that
AAH-related molecules are developmentally regulated in
the CNS.
AAH Promotes SH-Sy5y Cell Motility
The structural relationship of Humbug to AAH raised the
possibility that Humbug may also promote cell motility.
In previous studies, we used antisense oligodeoxynucle-
otides directed against the 5'end of the AAH mRNA to
demonstrate AAH's role in directional motility [14,16].
However, since those reagents would have also inhibited
Humbug expression, further studies were needed to deter-
mine if AAH alone or together with Humbug mediated
cell migration. Herein, we demonstrated that SH-Sy5y
cells transfected with pAAH, and not pHMBG, had signif-
icantly increased motility relative to pLuc-transfected con-
trol cells. Real time RT-PCR studies confirmed that
increased motility was associated with increased AAH and
not Humbug or Junctin expression. However, these find-
ings did not entirely exclude a role for Humbug since the
endogenous expression levels were already high, and fur-
ther increases may have had a negligible effect. In this
regard, Humbug has a demonstrated role in regulating
intracellular calcium [5,9,60], and although Humbug
may not directly mediate cell motility, its modulation of
intracellular pools of calcium may be critical for cytoskel-BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Role of Cdk-5 in the regulation of AAH Figure 6
Role of Cdk-5 in the regulation of AAH. SH-Sy5y cells were transfected with recombinant plasmids to over-express Luciferase 
(pLuc) as a negative control, Cdk-5, p35, p25, Cdk-5+p35, Cdk-5+p25, or pAAH. The cells were harvested 48 hours later to 
measure (A) Cdk-5 activity, (B) luciferase activity, (C) AAH immunoreactivity by Western blot analysis with b-actin loading 
control and (D) digital imaging of the Western blot results, (E) AAH mRNA with levels normalized to 18S, and (F) directional 
motility using the ALMI assay. The graphs depict the mean ± S.D. of results from 6 replicate independent cultures. Inter-group 
comparisons were made using ANOVA with post hoc Fisher LSD tests (*P < 0.001 and +P < 0.01 relative to pLuc-transfected 
control cells).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Role of Cdk-5 in the regulation of (A) Humbug and (B) Junctin expression Figure 7
Role of Cdk-5 in the regulation of (A) Humbug and (B) Junctin expression. SH-Sy5y cells were transfected with recombinant 
plasmids to over-express Luciferase (pLuc) as a negative control, Cdk-5, p25, p35, Cdk-5+p25, or Cdk-5+p35 as indicated in 
the box below the graphs. The cells were harvested 48 hours later to measure gene expression by real time quantitative RT-
PCR (see Methods). The graphs depict the mean ± S.D. of Humbug, or Junction expression with values normalized to 18S 
rRNA measured in the same samples. Statistical comparisons were made using ANOVA with post hoc Fisher LSD tests (*P < 
0.001 relative to pLuc-transfected control cells).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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Cdk-5 stimulation of AAH and Humbug expression is mediated by signaling through Erk MAPK and PI3 kinase: SH-Sy5y cells  were transfected with recombinant plasmids to over-express Luciferase or Cdk-5+p25 Figure 8
Cdk-5 stimulation of AAH and Humbug expression is mediated by signaling through Erk MAPK and PI3 kinase: SH-Sy5y cells 
were transfected with recombinant plasmids to over-express Luciferase or Cdk-5+p25. 36 hours after transfection, the cells 
were treated with vehicle (Con), PD98059 (PD9), or LY294002 (LY2). 12 hours later, i.e. 48 hours after transfection, the cells 
were harvested to measure (A) AAH, (B) Humbug, or (C) Junctin mRNA levels by real time quantitative RT-PCR. The graphs 
depict the mean ± S.D. of results normalized to 18S rRNA measured in the same samples. Statistical comparisons were made 
using ANOVA with post hoc Fisher LSD tests (*P < 0.001 relative to corresponding vehicle-treated control).BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
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eton reorganization that may be required for cell migra-
tion.
Growth Factor Regulation of AAH, Humbug, and Junctin 
Expression
Previous observations suggested that AAH expression was
modulated by growth factor stimulation. Since AAH,
Humbug, and Junctin are transcribed from the same gene,
it was of interest to determine the degree to which each of
these mRNA transcripts is regulated by growth factor stim-
ulation, particularly insulin and IGF-1. Our focus on insu-
lin and IGF-1 signaling pathways stemmed from earlier
studies demonstrating over-expression of AAH in hepato-
cellular carcinoma cells and in transgenic mice that over-
express IRS-1 [23]. The experiments herein demonstrated
that AAH and Humbug mRNA's were increased in
response to insulin or IGF-1 stimulation, and that Hum-
bug but not AAH expression was increased by NGF stimu-
lation. In addition, the studies showed that Junctin mRNA
levels were not significantly modulated by insulin, IGF-1,
or NGF. These results indicate that AAH and Humbug
expression are transcriptionally regulated by growth factor
stimulation, and that since the responses to growth factors
are similar but not identical, AAH and Humbug may be
differentially regulated by growth factor signaling.
Downstream Mediators of AAH and Humbug Expression in 
SH-Sy5y cells
The stimulatory effects of insulin and IGF-1 are mediated
by ligand binding and activation of the intrinsic receptor
tyrosine kinase [61], which then tyrosyl phosphorylates
exogenous cytosolic proteins, including insulin receptor
substrate molecules [38,62]. Tyrosyl phosphorylated IRS
molecules transmit signals downstream to promote a
broad range of functions including growth, survival,
energy metabolism, and motility [38,47,62]. The studies
herein demonstrated expression of IRS-1, IRS-2, and IRS-
4 in SH-Sy5y cells, but substantially higher levels of IRS-1
followed by IRS-4 compared with IRS-2, suggesting that
most of the insulin/IGF-1 mediated signaling is transmit-
ted through IRS-1. In the normal human brain, the pat-
tern of IRS expression differed from that observed in SH-
Sy5y cells in that the overall levels of IRS gene expression
were significantly lower, and IRS-1 was the least abundant
while IRS-2 was the most abundant of the three tran-
scripts. This alteration in IRS gene expression, particularly
with regard to the up-regulation of IRS-1 in SH-Sy5y cells,
is reminiscent of the findings in hepatocellular carcinoma
cells [63,64], and suggests that IRS protein levels may be
critical for regulating robustness of insulin and IGF-1-
transmitted signals, including those that stimulate AAH.
In this regard, it is noteworthy that in hepatocellular car-
cinoma cells, IRS-1 over-expression is associated with
increased insulin and IGF-1-stimulated growth and sur-
vival signaling, in addition to AAH over-expression rela-
tive to the normal liver [11,17,63-65].
Previous studies demonstrated that growth factor stimu-
lated cell motility is mediated by signaling through the
Erk MAPK and PI3 kinase-Akt pathways [49-52]. In addi-
tion, a probable role for Cdk-5 in relation to neuronal
migration during development was demonstrated in mice
that were deficient for the Cdk-5 gene [25,28,66-68]. A
potential link between insulin and IGF-1 signaling and
Cdk-5 activation was suggested by the previous finding
that p35 expression was increased by IGF-1 stimulation
[69]. Our studies demonstrated prominent IGF-1 stimula-
tion of AAH and Humbug, and significant inhibition of
these responses in cells treated with chemical inhibitors of
Erk MAPK, Akt, or Cdk-5. These results suggest that IGF-1
stimulated AAH and Humbug expression are signaled
through Erk MAPK, Akt, and Cdk-5, and that the effects of
these kinases on AAH and Humbug expression are medi-
ated at the level of transcription. The finding that chemi-
cal inhibitors of Erk MAPK or PI3 kinase blocked the Cdk-
5 stimulated AAH and Humbug expression provides evi-
dence for convergence of these pathways in the regulation
of gene expression. Finally, we also observed significantly
increased AAH protein but not mRNA expression follow-
ing LiCl treatment, which inhibits GSK-3β, independent
of Akt. The mechanism of this effect is under investiga-
tion, but preliminary results suggest that GSK-3β phos-
phorylation of AAH protein leads to its degradation
[Cheng, Tong, and de la Monte, Unpublished].
Previous studies demonstrated a definitive role for growth
factor stimulated MAPK mediated cell motility [70]. Erk
MAPK signaling can mediate motility of neoplastic cells
by activating Rac1 and RhoA GTPases, which promote
membrane ruffling, actin-cytoskeletal reorganization, and
attendant formation of lamellopodia and filopodia [71].
Similarly, the PI3 kinase/Akt pathway regulates the assem-
bly and re-organization of the actin cytoskeleton [72] and
motility [71] by activating Rac1/Cdc42 in response to
growth factor stimulation [73]. The downstream effects of
Rac1 on cell motility are mediated through Pak1 phos-
phorylation of LIM kinase [74,75], which phosphorylates
targets such as cofilin [76], which in turn promotes actin
depolymerization, thereby allowing changes in cell shape
and structure. In addition, Rac1 functions through Cdk-5
and p35 to phosphorylate and down-regulate Pak1, which
then results in increased neuronal migration [54]. There-
fore, growth factor stimulated Rac1 function has an
important role in dynamically regulating cytoskeletal
reorganization as required for cell migration. Importantly,
the convergence of pathways mediating IGF-1 stimulated
AAH and Humbug expression may occur through Rac1
and RhoA signaling.BMC Cell Biology 2006, 7:41 http://www.biomedcentral.com/1471-2121/7/41
Page 18 of 21
(page number not for citation purposes)
The finding that Cdk-5 activity has a functional role in
positively regulating AAH and Humbug expression in SH-
Sy5y cells is of particular interest because previous studies
provided in vivo evidence that Cdk-5 mediates neuronal
migration in the brain during development [28,66]. In
this regard, mutant mice lacking either the p35 or Cdk-5
gene have low levels of Cdk-5 activity and exhibit severe
defects in neuronal migration [24,28,66,77]. Cdk5 and its
regulatory partner, p35 or p39, have also been implicated
in growth cone motility during axon extension
[25,27,78]. One mechanism of Cdk-5-mediated neuronal
migration involves interactions between Cdk5-p35 and
Rac GTPase, which is required for growth cone motility
[25,54]. Cdk-5 can mediate its effects on neuronal migra-
tion through POU domain-containing transcription fac-
tors such as Brn 1 and Brn 2, which have roles in neuronal
migration [79] or MEF-2, which is a target of Cdk-5-medi-
ated phosphorylation [80], and has a known role in cellu-
lar differentiation [81,82]. Although Cdk-5-mediated
neuronal migration has been studied mainly in post-
mitotic neurons, the present work demonstrates that Cdk-
5 signaling is also relevant to immature proliferating and
transformed neuronal cells. Our results demonstrating
that increased Cdk-5 activity results in increased AAH and
Humbug expression are consistent with the concept that
Cdk-5 mediates neuronal migration [24,28,66,77], and
further suggest that AAH and Humbug are downstream
targets of Cdk-5 signaling.
Conclusion
AAH and Humbug are over-expressed in SH-Sy5y neurob-
lastoma cells, and their mRNAs are regulated by insulin/
IGF-1 signaling through Erk MAPK, PI3 kinase-Akt, and
Cdk-5, which are known mediators of cell migration.
Although AAH and Humbug share regulatory signaling
pathways, AAH and not Humbug mediates directional
motility in SH-Sy5y neuroblastoma cells.
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activated protein kinase
GSK: glycogen synthase kinase
IGF: insulin-like growth factor
IRS: insulin-receptor substrate
Fisher LSD: Fisher least significant difference
MICE: microtiter immunocytochemical ELISA
NGF: nerve growth factor
pAAH: AAH-expressing plasmid
pHMBG: Humbug-expressing plasmid
PI3 kinase: phosphatidylinositol 3-kinase
PKA: protein kinase A
pLuc: Luciferase-expressing plasmid
PMSF: phenylmethylsulphonylfluoride
PNET: primitive neuroectodermal tumor
RT-PCR: reverse transcriptase polymerase chain reaction
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
TBS: Tris buffered saline
TBST: Tris buffered saline with 0.05% Tween-20
TPCK: tosylphenylalanylchloromethane
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